Analysts Set Elanco Animal Health Incorporated (NYSE:ELAN) PT at $17.43

Elanco Animal Health Incorporated (NYSE:ELAN) has been assigned an average rating of “Hold” from the seven brokerages that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $17.00.

ELAN has been the topic of a number of recent research reports. Morgan Stanley downgraded shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $17.00 to $15.00 in a report on Thursday, September 19th. Stifel Nicolaus reiterated a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a report on Thursday, September 19th. Finally, Barclays lowered their target price on shares of Elanco Animal Health from $22.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday.

Insider Activity

In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of Elanco Animal Health stock in a transaction dated Monday, August 12th. The stock was bought at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the transaction, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. The trade was a 200.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other Elanco Animal Health news, CEO Jeffrey N. Simmons bought 100,000 shares of the stock in a transaction on Monday, August 12th. The stock was purchased at an average price of $13.01 per share, with a total value of $1,301,000.00. Following the completion of the purchase, the chief executive officer now owns 145,000 shares in the company, valued at $1,886,450. The trade was a 200.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Michael J. Harrington bought 3,500 shares of the stock in a transaction on Thursday, August 22nd. The shares were acquired at an average cost of $14.85 per share, with a total value of $51,975.00. Following the purchase, the director now owns 81,094 shares of the company’s stock, valued at approximately $1,204,245.90. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.57% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Hunter Associates Investment Management LLC boosted its holdings in Elanco Animal Health by 5.1% in the first quarter. Hunter Associates Investment Management LLC now owns 16,600 shares of the company’s stock valued at $269,000 after acquiring an additional 800 shares during the last quarter. 180 Wealth Advisors LLC raised its position in Elanco Animal Health by 3.6% in the 2nd quarter. 180 Wealth Advisors LLC now owns 25,716 shares of the company’s stock valued at $352,000 after buying an additional 893 shares during the last quarter. HBK Sorce Advisory LLC raised its position in Elanco Animal Health by 9.4% in the 2nd quarter. HBK Sorce Advisory LLC now owns 12,920 shares of the company’s stock valued at $186,000 after buying an additional 1,107 shares during the last quarter. Atomi Financial Group Inc. raised its position in Elanco Animal Health by 11.1% in the 2nd quarter. Atomi Financial Group Inc. now owns 12,260 shares of the company’s stock valued at $177,000 after buying an additional 1,221 shares during the last quarter. Finally, Keene & Associates Inc. increased its position in shares of Elanco Animal Health by 5.7% during the 3rd quarter. Keene & Associates Inc. now owns 22,945 shares of the company’s stock valued at $337,000 after purchasing an additional 1,240 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Stock Up 0.2 %

Shares of NYSE ELAN opened at $12.53 on Friday. The firm has a market capitalization of $6.19 billion, a PE ratio of -4.73, a price-to-earnings-growth ratio of 1.32 and a beta of 1.40. The company has a current ratio of 2.93, a quick ratio of 1.75 and a debt-to-equity ratio of 0.92. Elanco Animal Health has a 1 year low of $8.59 and a 1 year high of $18.80. The firm’s 50-day moving average is $14.23 and its 200-day moving average is $14.76.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.24 by $0.06. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter last year, the firm earned $0.18 EPS. Elanco Animal Health’s quarterly revenue was up 12.0% compared to the same quarter last year. Equities analysts expect that Elanco Animal Health will post 0.91 EPS for the current year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.